- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00835107
An Investigation of Sleep Architecture in Ziprasidone-Treated Bipolar Depression
December 14, 2015 updated by: Dr. Roumen Milev, Queen's University
This study uses polysomnographs(PSG) to investigate sleep patterns in patients with bipolar depression.
This is a double-blind, placebo-controlled, study of ziprasidone that is added to patients current medications.
The objective is to relate changes in slow wave and rapid eye movement sleep to changes in mood and overall illness severity.
Participants will be randomly assigned to add either placebo or ziprasidone to their current treatment regimen.
Participants make 3 to 4 study visits, over a 1 month period, at which they will be asked about their history, mood and sleep quality.
Participants will also have three in-home overnight polysomnographs.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
14
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ontario
-
Kingston, Ontario, Canada, K7L 4X3
- Providence Care Mental Health Services
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- A diagnosis of Bipolar Disorder Type 1,2 or NOS by Diagnostic and Statistical Manual of Mental Disorders- Fourth Edition (DSM-IV).
- Current depressive episode with a HAMD-17 of >16.
- Males or Females over age 18yrs.
- Inpatients or outpatients.
- Female patients of childbearing potential must be using a reliable method of contraception and have a negative urine human chorionic gonadotropin (HCG) test at enrolment.
- Able to understand and comply with the requirements of the study.
- Provision of written informed consent.
Exclusion Criteria:
- Current Manic, Hypomanic or Mixed episode, with YMRS > 12.
- Current or past diagnosis of Schizophrenia and Dementia.
- Pregnant women, or women in childbearing age, not willing to use appropriate contraception or women currently nursing.
- Patient on any other antipsychotic medication.
- Patients who, in the opinion of the investigator, pose an imminent risk of suicide or a danger to self or others.
- Known intolerance or lack of response to Ziprasidone, as judged by the investigator.
- Benzodiazepines and all other sleep-aids must be discontinued prior to participation in the study if they have not been at a stable dosage for the 4 weeks previous to entry into the study.
- No change to the current medication regime (excluding discontinuation of sleep aids and antipsychotic medications) is allowed 4 weeks prior to the first PSG reading.
- Administration of a depot antipsychotic injection within two dosing interval (for the depot) before randomization.
- Substance or alcohol dependence at enrolment or in the last three months (except for caffeine or nicotine dependence), as defined by DSM-IV criteria.
- Serious, unstable or inadequately treated medical illness as judged by the investigator.
- History of epilepsy or uncontrolled seizures.
- Involvement in the planning and conduct of the study.
- Previous enrolment in the present study.
- Participation in another drug trial within 4 weeks prior enrolment into this study or longer in accordance with local requirements.
- Patients with serum potassium, magnesium and/or calcium levels outside the normal range at baseline.
- Patients with marked liver function abnormalities at baseline, demonstrated by laboratory values, by judgment of the investigator.
- Known serological evidence of HIV, or acute or chronic hepatitis; donation of blood or blood products for transfusion prior to initiation of the treatment with study drug, during the study and for 30 days after the study has ended.
- Known history of QT prolongation (including congenital long QT syndrome).
- Recent acute myocardial infarction or uncompensated heart failure.
- Currently taking other drugs that are known to prolong the QT interval.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
PLACEBO_COMPARATOR: Sugar pill
|
placebo comparator, oral capsules, BID, for one month
|
EXPERIMENTAL: Ziprasidone
|
oral capsules, from 40-80 mg BID, for one month with the option to continue the medication after the study has been completed
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To assess the objective (polysomnographic) changes in sleep quality before and after introduction of Ziprasidone in treatment of patients with bipolar depression.
Time Frame: 1 month
|
1 month
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To assess the subjective changes in sleep quality parameters before and at different stages after introduction of ziprasidone in treatment, longitudinally, and to correlate these changes with measures of illness severity.
Time Frame: 1 month
|
1 month
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Anusha Baskaran, BScH, Queen's University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Cohrs S, Meier A, Neumann AC, Jordan W, Ruther E, Rodenbeck A. Improved sleep continuity and increased slow wave sleep and REM latency during ziprasidone treatment: a randomized, controlled, crossover trial of 12 healthy male subjects. J Clin Psychiatry. 2005 Aug;66(8):989-96. doi: 10.4088/jcp.v66n0805.
- Sharpley AL, Cowen PJ. Effect of pharmacologic treatments on the sleep of depressed patients. Biol Psychiatry. 1995 Jan 15;37(2):85-98. doi: 10.1016/0006-3223(94)00135-P.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2009
Primary Completion (ACTUAL)
June 1, 2011
Study Completion (ACTUAL)
June 1, 2011
Study Registration Dates
First Submitted
February 2, 2009
First Submitted That Met QC Criteria
February 2, 2009
First Posted (ESTIMATE)
February 3, 2009
Study Record Updates
Last Update Posted (ESTIMATE)
December 16, 2015
Last Update Submitted That Met QC Criteria
December 14, 2015
Last Verified
December 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Mental Disorders
- Mood Disorders
- Bipolar and Related Disorders
- Depression
- Depressive Disorder
- Bipolar Disorder
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Antipsychotic Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Serotonin Agents
- Dopamine Agents
- Serotonin Antagonists
- Dopamine Antagonists
- Ziprasidone
Other Study ID Numbers
- PSIY-287-08
- GA128250
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression, Bipolar
-
University Health Network, TorontoCompletedBipolar Disorder | Bipolar Depression | Bipolar I Depression | Bipolar II DepressionCanada
-
Brigham and Women's HospitalRecruitingDepression | Bipolar Disorder | Bipolar Depression | Major Depressive Episode | Bipolar I Depression | Bipolar II DepressionUnited States
-
Forest LaboratoriesGedeon Richter Ltd.CompletedDepression, BipolarUnited States, Ukraine, Bulgaria, Canada, Colombia, Russian Federation
-
Ewha Womans University Mokdong HospitalWithdrawnDepression, BipolarKorea, Republic of
-
Mclean HospitalTerminatedBipolar Depression Depressed PhaseUnited States
-
AstraZenecaCompletedAcute Bipolar DepressionBrazil, Mexico, Peru, Turkey, Argentina, Chile, Venezuela, Colombia, Guatemala
-
Valerie TaylorUniversity Health Network, TorontoActive, not recruitingBipolar DepressionCanada
-
National University of Ireland, Galway, IrelandStanley Medical Research InstituteCompletedBipolar DepressionIreland
-
Astellas Pharma IncCompleted
-
Mclean HospitalSuspendedBipolar Depression | Unipolar DepressionUnited States
Clinical Trials on ziprasidone hydrochloride
-
Dr. Reddy's Laboratories LimitedCompletedHealthyUnited States
-
Dr. Reddy's Laboratories LimitedCompleted
-
University Hospital FreiburgPfizerCompletedConduct Disorder | Oppositional Defiant DisorderGermany
-
Donald C. Goff, MDPfizerCompletedSchizophreniaUnited States
-
Pfizer's Upjohn has merged with Mylan to form Viatris...TerminatedAcute Mania | Bipolar Disorder, ManicTurkey, Italy, Germany, Greece, Spain
-
Bronx Psychiatric CenterPfizer; Buffalo Psychiatric Center; Rochester Psychiatric CenterCompletedSchizophrenia | Schizoaffective DisorderUnited States
-
Yale UniversityCompleted
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedBipolar DisorderUnited States
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedBipolar DisorderUnited States
-
Fundació Institut de Recerca de l'Hospital de la...Pfizer; Ministry of Health, Spain; REM-TAP NetworkCompletedBorderline Personality DisorderSpain